For the entry factor of SARS-CoV-2, it was KREMEN1 rather than ACE2 that dominated its myofibroblast elevation, while finally identifying the antifibrotic agent, Nintedanib, as a possible target for diabetes, hypertension, and hypertension-diabetes in SARS-CoV-2 infection-induced fibrotic lungs. Here, KREMEN1 is linked to hypertensive disorder.